This is a preview of subscription content, log in via an institution to check access.
Notes
2013 US dollars (direct costs only)
Reference
Minion LE, et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecologic Oncology : 10 Mar 2015. Available from: URL: http://doi.org/10.1016/j.ygyno.2015.02.027
Rights and permissions
About this article
Cite this article
Bevacizumab cost impacts cost effectiveness for cervical cancer. PharmacoEcon Outcomes News 724, 4 (2015). https://doi.org/10.1007/s40274-015-1982-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-1982-4